Journal of inflammation research · 2025
Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jianchao, Han Lu, Feng Shu, Lin Guoyuan, Zou Gaoliang, Huang Tao, Ran Tao, Zhao Xueke
Аннотация
PURPOSE: Cholestatic liver diseases, characterized by hepatic bile acid accumulation, often progress to fibrosis through incompletely understood mechanisms. While hydrophobic bile acids like glycochenodeoxycholic acid (GCDCA) are known to induce hepatocyte apoptosis or necrosis and their role in pyroptosis-a pro-inflammatory programmed cell death-remains unclear. This study investigates whether GCDCA drives hepatic stellate cell (HSC) activation via NLRP3 inflammasome-mediated pyroptosis in hepatocytes.
PATIENTS AND METHODS: Using L02 hepatocytes and LX2 HSCs, we evaluated the effects of GCDCA on NLRP3 inflammasome activation, gasdermin D (GSDMD)-dependent pyroptosis, and interleukin-1beta (IL-1β) secretion. Cells were treated with GCDCA (25-400 μM) ± lipopolysaccharide (LPS) to simulate cholestatic injury. Caspase-1 inhibition (Ac-YVAD-cmk), GSDMD knockdown (shRNA), and IL-1 receptor antagonist (IL-1RA) were employed to dissect mechanistic pathways. Pyroptosis (LDH release, Annexin V/PI staining), inflammasome components (NLRP3, ASC, caspase-1), GSDMD cleavage, IL-1β secretion (ELISA), and HSC activation (α-SMA, Collagen-I, proliferation/migration assays) were analyzed.
RESULTS: GCDCA alone upregulated NLRP3, pro-caspase-1, and pro-IL-1β in L02 cells but required LPS co-stimulation to trigger caspase-1 activation and GSDMD cleavage, indicating a dual-signal mechanism (priming + activation). This led to pyroptotic cell death (dose/time-dependent LDH release, Annexin V⁺/PI⁺ cells) and IL-1β secretion. GSDMD knockdown abolished pyroptosis and IL-1β release, while caspase-1 inhibition suppressed GSDMD-N-terminal (GSDMD-NT) generation. Conditioned media from pyroptotic hepatocytes activated LX2 HSCs, upregulating α-SMA and Collagen-I, and enhancing proliferation/migration-effects reversed by IL-1RA.
CONCLUSION: GCDCA promotes HSC activation via NLRP3 inflammasome-mediated pyroptosis in hepatocytes, driven by caspase-1-dependent GSDMD cleavage and IL-1β paracrine signaling. This mechanism bridges bile acid toxicity to fibrogenesis, highlighting therapeutic potential for targeting NLRP3-GSDMD-IL-1β signaling in cholestatic liver diseases.
PATIENTS AND METHODS: Using L02 hepatocytes and LX2 HSCs, we evaluated the effects of GCDCA on NLRP3 inflammasome activation, gasdermin D (GSDMD)-dependent pyroptosis, and interleukin-1beta (IL-1β) secretion. Cells were treated with GCDCA (25-400 μM) ± lipopolysaccharide (LPS) to simulate cholestatic injury. Caspase-1 inhibition (Ac-YVAD-cmk), GSDMD knockdown (shRNA), and IL-1 receptor antagonist (IL-1RA) were employed to dissect mechanistic pathways. Pyroptosis (LDH release, Annexin V/PI staining), inflammasome components (NLRP3, ASC, caspase-1), GSDMD cleavage, IL-1β secretion (ELISA), and HSC activation (α-SMA, Collagen-I, proliferation/migration assays) were analyzed.
RESULTS: GCDCA alone upregulated NLRP3, pro-caspase-1, and pro-IL-1β in L02 cells but required LPS co-stimulation to trigger caspase-1 activation and GSDMD cleavage, indicating a dual-signal mechanism (priming + activation). This led to pyroptotic cell death (dose/time-dependent LDH release, Annexin V⁺/PI⁺ cells) and IL-1β secretion. GSDMD knockdown abolished pyroptosis and IL-1β release, while caspase-1 inhibition suppressed GSDMD-N-terminal (GSDMD-NT) generation. Conditioned media from pyroptotic hepatocytes activated LX2 HSCs, upregulating α-SMA and Collagen-I, and enhancing proliferation/migration-effects reversed by IL-1RA.
CONCLUSION: GCDCA promotes HSC activation via NLRP3 inflammasome-mediated pyroptosis in hepatocytes, driven by caspase-1-dependent GSDMD cleavage and IL-1β paracrine signaling. This mechanism bridges bile acid toxicity to fibrogenesis, highlighting therapeutic potential for targeting NLRP3-GSDMD-IL-1β signaling in cholestatic liver diseases.